Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2009

Tsibris AM, Paredes R, Chadburn A, Su Z, Henrich TJ, Krambrink A, et al. Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211. Clin Infect Dis. 2009;48(5):642-9.

Lin Z, Yemelyanova AV, Gambhira R, Jagu S, Meyers C, Kirnbauer R, et al. Expression pattern and subcellular localization of human papillomavirus minor capsid protein L2. Am J Pathol. 2009;174(1):136-43.

Daniel VC, Marchionni L, Hierman JS, Rhodes JT, Devereux WL, Rudin CM, et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res. 2009;69(8):3364-73.

2008

McAllister SS, Gifford AM, Greiner AL, Kelleher SP, Saelzler MP, Ince TA, et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell. 2008;133(6):994-1005.

Rutgers EJ, Pusztai L, Bernards R. Are short-term or long-term recurrence rates more important in breast cancer screening? Ann Intern Med. 2008;149(5):357; author reply 357-8.

Siddiqui MT, Cohen C, Nassar A. Detecting high-grade cervical disease on ASC-H cytology: role of BD ProEx C and Digene Hybrid Capture II HPV DNA testing. Am J Clin Pathol. 2008;130(5):765-70.

Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S, et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst. 2008;100(11):815-25.

Feklistov A, Mekler V, Jiang Q, Westblade LF, Irschik H, Jansen R, et al. Rifamycins do not function by allosteric modulation of binding of Mg2+ to the RNA polymerase active center. Proc Natl Acad Sci U S A. 2008;105(39):14820-5.

Alsharif M, Aslan DL, Jessurun J, H Gulbahce E, Pambuccian SE. Cytologic diagnosis of metastatic seminoma to the prostate and urinary bladder: a case report. Diagn Cytopathol. 2008;36(10):734-8.

Niesvizky R, Jayabalan DS, Christos PJ, Furst JR, Naib T, Ely S, et al. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood. 2008;111(3):1101-9.